Samuel D Banister

Title: Innovations of Samuel D. Banister

Introduction

Samuel D. Banister is an accomplished inventor based in Castle Hill, Australia. He has made significant contributions to the field of neurodegenerative disease research through his innovative patents. With a total of 3 patents, Banister's work focuses on the development of compounds that activate Ppargc1a, which plays a crucial role in treating various neurodegenerative conditions.

Latest Patents

Banister's latest patents include the development of 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases. This genus of compounds, encompassed by formula (III), is designed to activate Ppargc1a, making them useful for treating a variety of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, motor neuron diseases, and demyelinating diseases. Another notable patent is for the compound 2-(4-tert-Butylphenyl)-1H-benzo[d]imidazol-5-ol, which also activates Ppargc1a and is beneficial for treating neuroinflammation and various neurodegenerative diseases.

Career Highlights

Samuel D. Banister is affiliated with Leland Stanford Junior University, where he continues to advance his research and innovation in the field of neurodegenerative diseases. His work has garnered attention for its potential impact on treatment options for patients suffering from these debilitating conditions.

Collaborations

Banister has collaborated with notable colleagues, including Edgar George Engleman and Khoa Dinh Nguyen. These partnerships have contributed to the development and refinement of his innovative compounds.

Conclusion

Samuel D. Banister's contributions to the field of neurodegenerative disease research through his patents highlight his commitment to innovation and improving patient outcomes. His work continues to pave the way for new treatment options in this critical area of healthcare.